Denne analyse antyder, at doseringsjusteringer baseret på de testede variable ikke forventes at give en relevant reduktion i den farmakokinetiske variation.
This analysis suggests that dose adjustment of rituximab with any of the tested covariates is not expected to result in a meaningful reduction in its pharmacokinetic variability.